Verisk Analytics stock rallies toward 6-month high after $2.5 billion accelerated stock buyback program announced

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 49 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 23%
  • Publisher: 97%

Business Business Headlines News

Business Business Latest News,Business Business Headlines

Shares of Verisk Analytics Inc. rallied 1.2% toward a six-month high in premarket trading Tuesday, after the data analytics company announced a $2.5 billion...

Shares of Verisk Analytics Inc.

rallied 1.2% toward a six-month high in premarket trading Tuesday, after the data analytics company announced a $2.5 billion accelerated share repurchase program. The ASR represented 8.6% of the company’s market capitalization of about $29.04 billion as of Monday’s closing prices. The company said it entered into the ASR with Citibank N.A. and Goldman Sachs & Co. LLC. The final settlement of the ASR is expected to occur during its fourth-quarter ending Dec. 31, 2023.

rallied 1.2% toward a six-month high in premarket trading Tuesday, after the data analytics company announced a $2.5 billion accelerated share repurchase program. The ASR represented 8.6% of the company’s market capitalization of about $29.04 billion as of Monday’s closing prices. The company said it entered into the ASR with Citibank N.A. and Goldman Sachs & Co. LLC. The final settlement of the ASR is expected to occur during its fourth-quarter ending Dec. 31, 2023.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

PayPal follow this

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

BioMarin’s stock falls after another company’s dwarfism drug moves into Phase 3 clinical trialsShares of BioMarin Pharmaceutical Inc. were down about 6.0% in premarket trading on Monday after BridgeBio Pharma Inc. shared positive Phase 2 clinical data...
Source: MarketWatch - 🏆 3. / 97 Read more »